Project Grant R01HL173365
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$814K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This $300,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by Gigamune, Inc. to develop an in vivo gene therapy approach for treating sickle cell disease. The project aims to assess the efficiency and specificity of a novel lentiviral vector platform for delivering CRISPR/Cas9 gene editing machinery to hematopoietic stem cells to knock out the BCL11A enhancer, with the goal of...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award of $889,998 under CFDA 93.837 (Cardiovascular Diseases Research) aims to develop a novel alpha-retroviral vector-based technology platform for in vivo and ex vivo delivery of genetic therapies to hematopoietic stem cells (HSCs). The key objectives are to: (I) develop integrating vectors to deliver a curative transgene to HSCs in vivo to treat X-linked severe combined immunodeficiency (X-SCID); (II) engineer virus-like...
This R15 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), aims to develop a nucleic acid nanoparticle (NANP) technology for efficiently delivering the CRISPR/Cas9 gene editing system into hematopoietic stem cells (HSCs). The goal is to enhance the targeting precision and efficacy of gene editing in HSCs to treat genetic blood disorders, such as sickle cell disease. The award provides $486,291 in...
This federal Project Grant award for $758,254, granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene editing therapy for treating hemophilia A. The project will combine lipid nanoparticle (LNP) delivery technology and CRISPR/Cas9 gene editing tools to permanently correct the mutated Factor VIII gene and restore Factor VIII expression in liver sinusoidal endothelial cells. The award will fund...
This Project Grant award of $786,188.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop a targeted gene therapy platform to prevent prosthetic bypass graft failure. The proposed approach involves using a novel biodegradable gelatin hydrogel to deliver small interfering RNA (siRNA) targeting specific genes, such as TSP-2 and MARCKS, that drive the development of intimal hyperplasia and graft...
This Project Grant award of $1,716,429.77 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene therapy approach for treating familial hypercholesterolemia (FH). The key objectives are: Comparing the efficiency and specificity of CRISPR-Cas9 gene editing methods, including lipid nanoparticles (LNPs), electroporation, and adeno-associated viruses (AAVs), to disrupt the CYPOR and ANGPTL3 genes in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to better understand the signaling and metabolic processes that allow hematopoietic stem cells (HSCs) to self-renew and avoid oxidative damage under hypoxic conditions in the bone marrow. The central goal is to explore methods to manipulate these processes in normoxic conditions in order to improve the functionality of HSCs for...
This $107,948 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to engineer hematopoietic stem and progenitor cells to produce B cells that secrete antibodies targeting PCSK9, a key regulator of cholesterol levels. The research, conducted at Stanford University from June 2025 through August 2028, will evaluate the safety and efficacy of this gene-targeted antibody (GT-AB) approach as a potential lifelong treatment for...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $579,425 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Case Western Reserve University (CWRU) to develop and improve the delivery of gene therapy treatments, including adeno-associated viral (AAV) and nanoparticle (NP) therapies, to the heart. The goal is to enhance the efficacy and safety of these therapies for treating cardiomyopathies, which are highly prevalent disorders of the cardiac muscle that often...